Radius Health Reports Second Quarter 2016 Financial and Operating Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Maxim Group Downgrades Radius Health (RDUS) to Sell
August 4, 2016 2:15 PM EDTMaxim Group downgraded Radius Health (NASDAQ: RDUS) from Hold to Sell with a price target of $24.00.
Analyst Jason McCarthy commented:
RDUS is "back" to an overvalued state. As such we are downgrading to Sell, from Hold. While we continue to believe that Abaloparatide-SC (and eventually the transdermal patch) will likely gain approval in 2017 in both the U.S. (PDUFA March 30, 2017) and Europe (EMA opinion early 2017), we believe significant challenges lay ahead in penetrating a mature Forteo Market, competition from Biosimilar Forteo in 2018 (from Teva [TEVA-$53.57-Buy]) and patients opting for alternative... MoreRadius Health (RDUS) Misses Q2 EPS by 6c
August 4, 2016 6:44 AM EDTRadius Health (NASDAQ: RDUS) reported Q2 EPS of ($1.01), $0.06 worse than the analyst estimate of ($0.95).
For earnings history and earnings-related data on Radius Health (RDUS) click here.
... More